CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 2 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $2,621,820 | -78.0% | 111,000 | -86.1% | 1.78% | -71.4% |
| Q3 2023 | $11,928,000 | +62.9% | 800,000 | +19.6% | 6.22% | +12.3% |
| Q2 2023 | $7,322,287 | +35.4% | 668,702 | +7.9% | 5.54% | +84.7% |
| Q1 2023 | $5,406,400 | -15.9% | 620,000 | -39.5% | 3.00% | -8.1% |
| Q4 2022 | $6,426,750 | +4.9% | 1,025,000 | -41.4% | 3.27% | +45.4% |
| Q3 2022 | $6,125,000 | +18.6% | 1,750,000 | 0.0% | 2.25% | +8.7% |
| Q2 2022 | $5,163,000 | -5.1% | 1,750,000 | 0.0% | 2.07% | +13.4% |
| Q1 2022 | $5,443,000 | -8.0% | 1,750,000 | 0.0% | 1.82% | +11.7% |
| Q4 2021 | $5,915,000 | – | 1,750,000 | – | 1.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |